Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (71-80 of 520) with videos related to

Pageof 52
Sort By:
European Heart Journal|November 15, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndromeJean-Claude Tardif, Marc A Pfeffer, Marie-Pierre Dubé, et al.
The American Journal of Medicine|April 22, 2018
Prescription of Statins to Women Poses New Clinical ChallengesMadeline Pung, Janet Robishaw, Marc A Pfeffer, et al.
The New England Journal of Medicine|March 15, 2013
Aliskiren in type 2 diabetes and cardiorenal end pointsMarc A Pfeffer, Barry M Brenner, John J V McMurray
Circulation|November 23, 2006
Variable impact of combining fatal and nonfatal end points in heart failure trialsHicham Skali, Marc A Pfeffer, Jacobus Lubsen, et al.
American Heart Journal|June 24, 2010
Maximizing scientific knowledge from randomized clinical trialsFinn Gustafsson, Dan Atar, Bertram Pitt, et al.
The American Journal of Medicine|February 5, 2020
Aspirin in Primary Prevention: Needs Individual Clinical JudgmentsAlexander Gitin, Marc A Pfeffer, David L DeMets, et al.
Clinical Chemistry|April 27, 2011
HMG CoA reduction in patients with average cholesterol concentrationsEugene Braunwald, Frank M Sacks, Marc A Pfeffer, et al.
Archives of Internal Medicine|March 25, 2009
Red blood cell distribution width and mortality risk in a community-based prospective cohortTodd S Perlstein, Jennifer Weuve, Marc A Pfeffer, et al.
Circulation|November 17, 2004
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?John J V McMurray, Marc A Pfeffer, Karl Swedberg, et al.
Journal of Biopharmaceutical Statistics|June 14, 2014
Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trialsThomas R Fleming, Charles H Hennekens, Marc A Pfeffer, et al.
Pageof 52

Showing results (71-80 of 520) with videos related to

Sort By:
Pageof 52
European Heart Journal|November 15, 2022
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndromeJean-Claude Tardif, Marc A Pfeffer, Marie-Pierre Dubé, et al.
The American Journal of Medicine|April 22, 2018
Prescription of Statins to Women Poses New Clinical ChallengesMadeline Pung, Janet Robishaw, Marc A Pfeffer, et al.
The New England Journal of Medicine|March 15, 2013
Aliskiren in type 2 diabetes and cardiorenal end pointsMarc A Pfeffer, Barry M Brenner, John J V McMurray
Circulation|November 23, 2006
Variable impact of combining fatal and nonfatal end points in heart failure trialsHicham Skali, Marc A Pfeffer, Jacobus Lubsen, et al.
American Heart Journal|June 24, 2010
Maximizing scientific knowledge from randomized clinical trialsFinn Gustafsson, Dan Atar, Bertram Pitt, et al.
The American Journal of Medicine|February 5, 2020
Aspirin in Primary Prevention: Needs Individual Clinical JudgmentsAlexander Gitin, Marc A Pfeffer, David L DeMets, et al.
Clinical Chemistry|April 27, 2011
HMG CoA reduction in patients with average cholesterol concentrationsEugene Braunwald, Frank M Sacks, Marc A Pfeffer, et al.
Archives of Internal Medicine|March 25, 2009
Red blood cell distribution width and mortality risk in a community-based prospective cohortTodd S Perlstein, Jennifer Weuve, Marc A Pfeffer, et al.
Circulation|November 17, 2004
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?John J V McMurray, Marc A Pfeffer, Karl Swedberg, et al.
Journal of Biopharmaceutical Statistics|June 14, 2014
Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trialsThomas R Fleming, Charles H Hennekens, Marc A Pfeffer, et al.
Pageof 52